Aptose Biosciences (NASDAQ:APTO) Price Target Lowered to $2.00 at HC Wainwright

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) had its target price trimmed by HC Wainwright from $7.00 to $2.00 in a report issued on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock.

Separately, StockNews.com assumed coverage on Aptose Biosciences in a report on Wednesday, November 13th. They issued a “hold” rating on the stock.

Aptose Biosciences Price Performance

Shares of NASDAQ APTO opened at $0.27 on Wednesday. The firm has a fifty day moving average of $0.38 and a 200-day moving average of $0.62. Aptose Biosciences has a 52-week low of $0.27 and a 52-week high of $2.91.

Institutional Investors Weigh In On Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Armistice Capital LLC bought a new position in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned approximately 9.46% of Aptose Biosciences at the end of the most recent quarter. Institutional investors and hedge funds own 26.62% of the company’s stock.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.